Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retinal Vasoreactivity as a Marker for SVD Progression and Cilostazol Efficacy
NCT04753970Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Feb 2021
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cilostazol in Cerebral Small Vessel Disease (CSVD), sponsored by Mayo Clinic. Started Feb 2021; status: recruiting.
02
Drugs
cilostazol
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT04753970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04753970.